About 30 results found for searched term "BMS-5" (0.006 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1649 | Apixaban | Factor Xa |
| BMS-562247-01 | ||
| Apixaban is a highly selective, reversible and orally active direct factor Xa inhibitor with an IC50 of 0.22±0.02 µM. | ||
| M1657 | Atazanavir Sulfate | HIV Protease |
| BMS-232632, Reyataz, CGP-73547 | ||
| Atazanavir sulfate (BMS-232632, Reyataz) is an azapeptide inhibitor of HIV-1 protease. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. | ||
| M1681 | BMS-707035 | Integrase |
| BMS707035 | ||
| BMS-707035 is an HIV-1 integrase (IN) inhibitor. HIV-1 integrase (IN) represents a therapeutically advantageous viral target to treat HIV/AIDS in the clinic. | ||
| M1682 | BMS-777607 | c-Met |
| BMS 817378; CAS# 1025720-94-8 | ||
| BMS-777607 is a selective and potent small-molecule met kinase inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. | ||
| M1684 | BMS-599626 | EGFR/HER2 |
| AC480 | ||
| BMS-599626 (AC480) is an orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. | ||
| M1687 | Brivanib alaninate | VEGFR/PDGFR |
| BMS-582664 | ||
| Brivanib alaninate (BMS-582664) is a novel, orally available and selective receptor tyrosine kinase inhibitor of VEGF-R2 and FGF-R1 and -2. | ||
| M1688 | Brivanib | VEGFR/PDGFR |
| BMS-540215 | ||
| Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 value of 25 nM. | ||
| M1701 | Dasatinib | Src-bcr-Abl |
| BMS-354825 | ||
| Dasatinib (BMS-354825) is a small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively. | ||
| M1757 | XL-184 | c-Met |
| Cabozantinib, BMS-907351，Cabometyx | ||
| XL184 is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively. | ||
| M1843 | BMS-790052 | HCV Protease |
| Daclatasvir; EBP 883 | ||
| BMS-790052 (Daclatasvir) is a first-in-class, nonstructural protein 5A (NS5A) replication complex inhibitor with an EC50 of 9-50 pM. | ||
| M1937 | Dapagliflozin | SGLT |
| BMS-512148 | ||
| Dapagliflozin (BMS-512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). | ||
| M1957 | BMS-536924 | IGF-1R |
| Bms-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50 of 100 nM and 73 nM, respectively. It also showed moderate inhibitory activity against Mek, Fak and Lck, but almost no inhibitory activity against Akt1 and MAPK1/2. | ||
| M2192 | BMS-754807 | IGF-1R |
| Bms-754807 is a potent igf-1r /InsR reversible inhibitor with an IC50 of 1.8 nM/1.7 nM and also inhibits the activity of Met, RON, TrkA, TrkB, AurA and AurB with an IC50 value of 6,44,7,4, respectively. At 9 and 25 nM, it has almost no inhibitory activity against Flt3, Lck, MK2, PKA and PKC. | ||
| M2254 | Gatifloxacin | Antibiotic |
| Gatiflo; AM-1155; BMS-206584; PD135432 | ||
| Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family. | ||
| M2323 | BMS-265246 | CDK |
| BMS265246 is a potent and selective CDK inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively. | ||
| M2336 | BMS-345541 hydrochloride | IκB/IKK |
| BMS-345541 hcl | ||
| BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of IKK (IC50 values of 0.3 μM and 4 μM for IKK-2 and IKK-1 respectively). | ||
| M2340 | Asunaprevir | HCV Protease |
| BMS-650032 | ||
| Asunaprevir (BMS-650032) is a novel inhibitor of the hepatitis C virus enzyme serine protease NS3. | ||
| M2462 | BMS-345541 | IκB/IKK |
| BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM, respectively. | ||
| M2464 | BMS-690514 | EGFR/HER2 |
| BMS-690514 is a potent inhibitor of EGFR and VEGFR2 with IC50 of 5 nM and 50 nM, respectively. | ||
| M2466 | BMS-911543 | JAK |
| BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. | ||
| M3275 | Irbesartan | Angiotensin Receptor |
| SR-47436; BMS-186295 | ||
| Irbesartan (SR-47436, BMS-186295) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM. | ||
| M3693 | Daclatasvir dihydrochloride | HCV Protease |
| BMS790052 dihydrochloride | ||
| Daclatasvir is a potent hepatitis C virus (HCV) NS5A protein inhibitor with picomolar EC50 value . | ||
| M3725 | TAS-103 dihydrochloride | Topoisomerase |
| BMS-247615 | ||
| TAS-103, also known as BMS-247615, is a quinoline derivative that displays antitumor activity in murine and human tumor models. | ||
| M3768 | Ixabepilone | Microtubule |
| Ixempra, BMS-247550, NSC 710428 | ||
| Ixabepilone (BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound with clinical activity in a range of solid tumors. | ||
| M4138 | Deucravacitinib (BMS-986165) | JAK |
| BMS986165 | ||
| Deucravacitinib (BMS-986165) is a first-in-class, selective, orally bioavailable inhibitor of TYK2 transitions.Deucravacitinib selectively binds the TYK2 pseudokinase (JH2) structural domain with an IC50 of 1.0 nM and a Ki value of 0.02 nM. Deucravacitinib (BMS-986165) blocks receptor-mediated Tyk2 activation by stably regulating the JH2 structural domain. deucravacitinib also inhibits the IL-12/23 and type I IFN pathways. deucravacitinib may be used in psoriasis research. | ||
| M5125 | BMS-687453 | PPAR |
| Bms-687453 is an effective and selective PPARα agonist with EC50 and IC50 of 10 nM and 260 nM for human PPARα, respectively. The EC50 and IC50 values were 4100 nM and >15000 nM, respectively. | ||
| M5290 | (±)-SLV-319 | Cannabinoid |
| (±)-Ibipinibant; BMS-646256 | ||
| (±)-SLV319 (Ibipinabant) is a potent and selective CB1 receptor antagonist (Ki = 7.8 nM). Exhibits 1000-fold selectivity for CB1 over CB2 receptors. Inhibits CP 55,940-induced hypotension and WIN 55,212-2-induced hypothermia in vivo. | ||
| M5551 | Dapagliflozin ((2S)-1,2-propanediol, hydrate) | SGLT |
| BMS-512148 (2S)-1,2-propanediol, hydrate | ||
| Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. | ||
| M5552 | Dasatinib HCl | Src-bcr-Abl |
| BMS 354825 hydrochloride | ||
| Dasatinib(BMS-354825) hydrochloride is a potent and dual Abl/ Src inhibitor IC50 of ＜1 nM/0.8 nM respectively; also inhibit c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM. | ||
| M5553 | Dasatinib Monohydrate | Src-bcr-Abl |
| BMS-354825 Monohydrate | ||
| Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
